Technical Data
A2275-59X
APP, NT (Amyloid beta A4 Protein, APP, ABPP, Alzheimer Disease Amyloid Protein, Cerebral Vascular Amyloid Peptide, CVAP, Protease Nexin-II, PN-II, APPI, PreA4, A4, AD1)
Description:
Amyloid Beta-protein/amyloid A4 or amyloid Beta-peptide is derived from the amyloid Beta-precursor protein. Beta-amyloid is an extracellular filamentous protein component of amyloid cores, neuritic plaques and is also found as a deposit in neurofibrillary tangles. In man, Alzheimer's disease is the most common cause of senile dementia and is characterizes by abnormal filamentous protein deposits in the brain. Beta-amyloid deposits are also detected in Lewy body dementia, Down's syndrome, amyloidosis (Dutch type) and in the Guam Parkinson-Dementia complex.

Applications:
Suitable for use in Immunohistochemistry. Other applications not tested.

Recommended Dilution:
Optimal dilutions to be determined by the researcher.

Storage and Stability:
Lyophilized powder may be stored at -20C. Stable for 12 months at -20C. Reconstitute with sterile ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20C. Reconstituted product is stable for 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
TypeIsotypeCloneGrade
MabIgG1,k12K251Affinity Purified
SizeStorageShippingSourceHost
500ug-20CBlue IceHumanMouse
Concentration:
Not determined
Immunogen:
Full length human beta amyloid peptide 43
Purity:
Purified by Protein G affinity chromatography.
Form
Supplied as a lyophilized powder from 0.01M PBS, pH 7.2. Reconstitute in ddH2O to 1mg/ml.
Specificity:
Recognizes the N-terminal sequence of human beta amyloid peptides, and full length beta amyloid peptide 40, 42 and 43.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.